Capricor治疗 CAPR 深 沪
等待开盘 08-02 09:30:00 美东时间
8.08
-0.100
-1.22%
华盛通- 最 高8.28
- 今 开7.93
- 成交量 88.24万股
- 最 低 7.72
- 昨 收 8.18
- 总市值 3.69亿
- 52周最高 23.40
- 市盈率 静 --
- 换手率 1.93%
- 52周最低 3.71
- 委 比 -7.83%
- 总股本 4570.78万
- 历史最高 171.50
- 量 比 0.58
- 振 幅 6.85%
- 历史最低 0.88
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | FDA人事变动或缓解监管压力，REPL飙涨超101%；SUPX大涨44%
FDA人事变动或缓解监管压力，REPL飙涨超101%；推出英伟达Blackwell架构AI服务器，SUPX大涨44%>>
07-31 14:30
Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs
Sarepta Therapeutics (NASDAQ:SRPT), Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics division, recently witnessed sharp increa...
07-30 22:27
Capricor Therapeutics To Host July 29 Webinar With PPMD On Deramiocel BLA Progress And Cardiomyopathy In Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it will host a webinar in collaboration with Parent
07-28 21:07
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics will host a webinar with Parent Project Muscular Dystrophy on July 29, 2025, at 1:00 p.m. ET. The webinar will review the status of Capricor’s BLA for Deramiocel, discuss cardiomyopathy in Duchenne muscular dystrophy, and answer community questions. Deramiocel, an allogeneic cardiac-derived cell therapy, is in late-stage development for Duchenne Muscular Dystrophy.
07-28 13:00
Capricor’s Trial Data Deception Triggers Major Lawsuit
In a dramatic turn of events, Capricor Therapeutics, Inc. finds itself at the c...
07-18 23:45
美股大行评级 | 潜在涨幅94.06%！摩根大通上调BioMarin制药目标价至113美元，维持"超配"评级
今日重点评级关注：摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从108美元升至113美元；Oppenheimer：维持P10"跑赢大市"评级，目标价从20美元升至21美元
07-15 09:23
美股大行评级 | 潜在涨幅62.34%！NioCorp Developments获Maxim Group升目标价至5美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持NioCorp Developments"买入"评级，目标价从4美元升至5美元；花旗：维持BridgeBio Pharma"买入"评级，目标价从58美元升至67美元
07-14 08:34
FDA驳回肌肉疾病药物申请 Capricor Therapeutics(CAPR.US)盘前暴跌
由于美国监管机构驳回了公司一款致命性肌肉疾病治疗药物的申请，Capricor Therapeutics(CAPR.US)股价一度暴跌逾60%。
07-11 21:12
Capricor Therapeutics Stock (CAPR) Plummets 40% on FDA Rejection
Capricor Therapeutics stock plummeted on Friday after the company received a re...
07-11 21:05
